Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.
October 31, 2023
Company Announcement No. 42
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the European Patent Office (EPO) regarding the issuance of a patent for the subsidiary's wound-healing drug combination (RXN-022) and the company's treatment for colorectal cancer.
Reponex Pharmaceuticals A/S (Reponex) announced today that the EPO has issued an "Intention To Grant" for EU patent applications numbers 15724673.7 and 19701467.3.
The former application, which pertains to the wound-healing candidate RNX-022, describes a method for treating chronic wounds by applying a hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF), sucralfate, and hyaluronan to accelerate wound healing.
The latter application concerns the colorectal cancer candidate RNX-051 and describes a method for suppressing bacterial layers (biofilms) protecting the cancerous tumor or adenomas (potential tumors) from the body's immune system in the colon or rectum.
A Notice of “Intention to Grant" indicates that the EPO intends to issue the patents after certain standard procedural steps are completed, with the patents expected to be granted within 2 months, valid until 2035 and 2039, respectively.
"It is with great joy, that we today received the European Patent Office's notification of their 'intention to grant' for Reponex's treatment of venous leg ulcers. This decision strengthens our belief in the product's significance and the innovative potential it represents.
But it doesn't stop there; Reponex has also concurrently obtained 'intention to grant' for our treatment method, which combines two specific antibiotics aimed at selectively combating the bacteria that protect cancerous tumors in the colon and rectum from the body's immune system. This is a significant step forward in our efforts to contribute to cancer treatment and provide hope for those battling this dreadful disease.
We are deeply grateful for EPO's recognition and look forward to continuing our work to make these treatments accessible to those who need them most," says Thomas Kaas Selsø, CEO of Pharma Equity Group A/S.
According to Grand View Research, the global wound care market was valued at USD 21.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.15% from 2023 to 2030.
According to the World Health Organization (WHO) and The International Agency for Research on Cancer (IARC), the global colorectal cancer market was valued at USD 9.4 billion in 2020. Each year, approximately 57 million new cases of adenomas and about 1.5 million new cases of colorectal cancer are reported in Western countries.
For further information, please contact:
Thomas Kaas Selsø, CEO
Phone: +45 4022 2114
Email: tks@pharmaequitygroup.com
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.
The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub11.12.2023 16:30:00 CET | Press release
Press Release Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub Nokia Bell Labs is reaffirming its commitment to New Jersey, upholding its 80-year heritage of cutting-edge research and innovation in the state.Move will establish New Brunswick as Nokia’s new R&D hub on the East Coast and affirms Nokia’s commitment to this fast-growing innovation zone in the US. 11 December 2023 New Brunswick, New Jersey – Nokia today announced plans to relocate its campus in Murray Hill, NJ by 2028 to a new state-of-the-art research and development (R&D) facility in the burgeoning innovation and technology hub in New Brunswick, NJ. The new leading-edge R&D facility will propel Nokia Bell Labs to adapt and evolve to remain at the forefront of cutting-edge technology and continue contributing to a legacy of innovation in New Jersey. As the industrial research arm of Nokia, Nokia Bell Labs has always moved ahead of
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties11.12.2023 16:30:00 CET | Press release
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Anne Mette Toftegaard, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties. Please see attached report. Contact Please direct any questions regarding this announcement to: Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02 Attachment AS 26 2023 - Report on trading Anne Mette Toftegaard
Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations11.12.2023 16:30:00 CET | Press release
Press Release Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations Nokia Innovation Framework evolving with new venture studio and venture partnerships to unleash the full commercial potential of Nokia Bell Labs technologies outside of Nokia’s strategic perimeters. A new venture studio with America’s Frontier Fund and Roadrunner Venture Studios for commercializing the next generation of critical technology for the US will be situated in New Jersey, the iconic home of Bell Labs innovation for over 80 years.New venture partnership with Celesta Capital will invest in scaling ventures built with deep technologies from Nokia Bell Labs. 11 December 2023 Murray Hill, New Jersey – Nokia today announced an evolution to its Innovation Framework to unlock the full commercial potential of Nokia Bell Labs’ innovations across industries and expand efforts in external startup creation in the US with new partnerships and a new vent
Alm. Brand - Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med Alm. Brand A/S aktier11.12.2023 16:30:00 CET | pressemeddelelse
Alm. Brand - Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med Alm. Brand A/S aktier I henhold til EU-forordning 596/2014 artikel 19 og i henhold til fuldmagt til at indberette handler for Anne Mette Toftegaard skal Alm. Brand A/S hermed indberette oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med Alm. Brand A/S aktier eller andre værdipapirer, som er knyttet til disse aktier. Se vedhæftede indberetning. Kontakt Eventuelle henvendelser vedrørende denne fondsbørsmeddelelse bedes rettet til Senior Investor Relations Officer Mikael Bo Larsen, mobil 51 43 80 02. Vedhæftet fil AS 26 2023 - Indberetning af transaktioner Anne Mette Toftegaard
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties11.12.2023 16:30:00 CET | Press release
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Rasmus Werner Nielsen, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties. Please see attached report. Contact Please direct any questions regarding this announcement to: Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02 Attachment AS 25 2023 - Report on trading_Rasmus Werner Nielsen